Exudative Age Related Macular Degeneration Clinical Trial
Official title:
OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy
Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monotherapy
This study is a 48 week, single center, randomized controlled clinical trial. Approximately 150 subjects will be randomized into three separate arms. This study compares the efficacy of standard of care Lucentis (ranibizumab) monotherapy versus OCTA-Directed PDT Triple Therapy with Lucentis (ranibizumab), PDT with Visudyne (verteporfin), and Triescence (triamcinolone acetonide) in treatment-naïve patients with Exudative Age-Related Macular Degeneration. OCTA-Directed PDT Double Therapy with Lucentis (ranibizumab) and PDT with Visudyne (verteporfin) will also be tested to confirm the hypothesis that steroids are necessary. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03071055 -
Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
|
Phase 2 | |
| Completed |
NCT00927303 -
The Spectralis-Cirrus Study
|
N/A | |
| Completed |
NCT04723160 -
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
|
||
| Completed |
NCT02732899 -
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
|
Phase 2 |